Skip to main content

Advertisement

SpringerLink
Log in

Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial

  • Original
  • Published:
Intensive Care Medicine Aims and scope Submit manuscript

Abstract

Objective

To compare the effects of arginine-vasopressin (AVP) and norepinephrine (NE) on hemodynamic variables, organ dysfunction, and adverse events in early hyperdynamic septic shock.

Design and setting

Randomized, controlled, open-label trial.

Patients and participants

Twenty-three patients with early (12 h) hyperdynamic septic shock in two teaching hospitals.

Interventions

AVP (0.04–0.20 U min–1, n = 13) as a single agent or NE (0.1–2.8 μg kg–1 min–1, n = 10) infusion for 48 h to achieve mean arterial pressure at or above 70 mmHg.

Measurements and results

Hemodynamic parameters and Sequential Organ Failure Assessment (SOFA) score were measured. AVP and NE equally increased mean arterial pressure over 48 h, but NE was required in 36% of AVP patients at 48 h. Compared to baseline, AVP increased systemic vascular resistance, decreased exposure to NE, decreased cardiac output by decreasing heart rate, increased creatinine clearance, and improved SOFA score. The PrCO2 – PaCO2 difference remained stable throughout the study. One AVP patient developed acute coronary syndrome with dose-dependent ECG changes. Three patients in both groups died during their ICU stay.

Conclusion

In early hyperdynamic septic shock, the administration of high-dose AVP as a single agent fails to increase mean arterial pressure in the first hour but maintains it above 70 mmHg in two-thirds of patients at 48 h. AVP decreases NE exposure, has no effect on the PrCO2 – PaCO2 difference, and improves renal function and SOFA score.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hoyert DL, Kung HC, Smith BL (2005) Deaths: preliminary data for 2003. Natl Vital Stat Rep 53:1–48

    Google Scholar 

  2. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29:1303–1310

    Article  PubMed  CAS  Google Scholar 

  3. Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, Moreno R, Carlet J, Le Gall JR, Payen D (2006) Sepsis Occurrence in Acutely Ill Patients Investigators. Crit Care Med 34:344–353

    Article  PubMed  Google Scholar 

  4. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M, for the Early Goal-Directed Therapy Collaborative Group (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345:1368–1377

    Article  PubMed  CAS  Google Scholar 

  5. Müllner M, Urbanek B, Havel C, Losert H, Waechter F, Gamper G (2004) Vasopressors for shock. Cochrane Database of Systematic Reviews, issue 3: CD003709

    Google Scholar 

  6. Landry DW, Levin HR, Gallant EM, Ashton RC Jr, Seo S, D'Alessandro D, Oz MC, Oliver JA (1997) Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 95:1122–1125

    PubMed  CAS  Google Scholar 

  7. Sharshar T, Blanchard A, Paillard M, Raphael JC, Gajdos P, Annane D (2003) Circulating vasopressin levels in septic shock. Crit Care Med 31:1752–1758

    Article  PubMed  CAS  Google Scholar 

  8. Luckner G, Dunser MW, Jochberger S, Mayr VD, Wenzel V, Ulmer H, Schmid S, Knotzer H, Pajk W, Hasibeder W, Mayr AJ, Friesenecker B (2005) Arginine vasopressin in 316 patients with advanced vasodilatory shock. Crit Care Med 33:2659–2666

    Article  PubMed  CAS  Google Scholar 

  9. Hall LG, Oyen LJ, Taner CB, Cullinane DC, Baird TK, Cha SS, Sawyer MD (2004) Fixed-dose vasopressin compared with titrated dopamine and norepinephrine as initial vasopressor therapy for septic shock. Pharmacotherapy 24:1002–1012

    Article  PubMed  CAS  Google Scholar 

  10. Obritsch MD, Jung R, Fish DN, MacLaren R (2004) Effects of continuous vasopressin infusion in patients with septic shock. Ann Pharmacother 38:1117–1122

    Article  PubMed  CAS  Google Scholar 

  11. Klinzing S, Simon M, Reinhart K, Bredle DL, Meier-Hellmann A (2003) High-dose vasopressin is not superior to norepinephrine in septic shock. Crit Care Med 31:2646–2650

    Article  PubMed  CAS  Google Scholar 

  12. Haren FMP van, Rozendaal FW, van der Hoeven JG (2003) The effect of vasopressin on gastric perfusion in catecholamine-dependent patients in septic shock. Chest 124:2256–2260

    Article  PubMed  Google Scholar 

  13. Dunser MW, Mayr AJ, Ulmer H, Ritsch N, Knotzer H, Pajk W, Luckner G, Mutz NJ, Hasibeder WR (2001) The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: a retrospective analysis. Anesth Analg 93:7–13

    Article  PubMed  CAS  Google Scholar 

  14. Tsuneyoshi I, Yamada H, Kakihana Y, Nakamura M, Nakano Y, Boyle WA (2001) Hemodynamic and metabolic effects of low dose vasopressin infusions in vasodilatory septic shock. Crit Care Med 29:487–493

    Article  PubMed  CAS  Google Scholar 

  15. Holmes CL, Walley KR, Chittock DR, Lehman T, Russell JA (2001) The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Care Med 27:1416–1421

    Article  PubMed  CAS  Google Scholar 

  16. Landry DW, Levin HR, Gallant EM, Seo S, D'Alessandro D, Oz MC, Oliver JA (1997) Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med 25:1279–1282

    Article  PubMed  CAS  Google Scholar 

  17. Dunser MW, Mayr AJ, Ulmer H, Knotzer H, Sumann G, Pajk W, Friesenecker B, Hasibeder WR (2003) Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation 107:2313–2319

    Article  PubMed  CAS  Google Scholar 

  18. Patel BM, Chittock DR, Russell JA, Walley KR (2002) Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 96:576–582

    Article  PubMed  CAS  Google Scholar 

  19. Malay MB, Ashton RC Jr, Landry DW, Townsend RN (1999) Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma 47:699–703

    Article  PubMed  CAS  Google Scholar 

  20. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20:864–874

    Google Scholar 

  21. Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troche G, Chaumet-Riffaut P, Bellissant E (2002) Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288:862–871

    Article  PubMed  CAS  Google Scholar 

  22. Jochberger S, Mayr VD, Luckner G, Wenzel V, Ulmer H, Schmid S, Knotzer H, Pajk W, Hasibeder W, Friesenecker B, Mayr AJ, Dünser MW (2006) Serum vasopressin concentrations in critically ill patients. Crit Care Med 34:293–299

    Article  PubMed  CAS  Google Scholar 

  23. Bucher M, Hobbhahn J, Taeger K, Kurtz A (2002) Cytokine-mediated down-regulation of vasopressin V1A receptors during acute endotoxemia in rats. Am J Physiol Regul Integr Comp Physiol 282:R979–R984

    PubMed  CAS  Google Scholar 

  24. Leone M, Boyle WA (2006) Decreased vasopressin responsiveness in vasodilatory septic shock-like conditions. Crit Care Med 34:1126–1130

    Article  PubMed  CAS  Google Scholar 

  25. Levy MM, Macias WL, Vincent JL, Russell JA, Silva E, Trzaskoma B, Williams MD (2005) Early changes in organ function predict eventual survival in severe sepsis. Crit Care Med 33:2194–2201

    Article  PubMed  Google Scholar 

  26. Ferreira FL, Bota DP, Bross A, Mélot C, Vincent JL (2001) Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA 286:1754–1758

    Article  PubMed  CAS  Google Scholar 

  27. Moreno R, Vincent JL, Matos R, Mendonca A, Cantraine F, Thijs L, Takala J, Sprung C, Antonelli M, Bruining H, Willatts S (1999) The use of maximum SOFA score to quantify organ dysfunction/failure in intensive care. Results of a prospective, multicentre study. Intensive Care Med 25:686–696

    Article  PubMed  CAS  Google Scholar 

  28. Lévy B, Vallée C, Lauzier F, Plante GE, Mansart A, Mallie JP, Lesur O (2004) Comparative effects of vasopressin, norepinephrine, and L-canavanine, a selective inhibitor of inducible nitric oxide synthase, in endotoxic shock. Am J Physiol Heart Circ Physiol 287:H209–H215

    Article  PubMed  Google Scholar 

  29. Albert M, Losser MR, Hayon D, Faivre V, Payen D (2004) Systemic and renal macro- and microcirculatory responses to arginine vasopressin in endotoxic rabbits. Crit Care Med 32:1891–1898

    Article  PubMed  CAS  Google Scholar 

  30. Edwards RM, Trizna W, Kinter LB (1989) Renal microvascular effects of vasopressin and vasopressin antagonists. Am J Physiol 256:F274–F278

    PubMed  CAS  Google Scholar 

  31. Rudichenko VM, Beierwaltes WH (1995) Arginine vasopressin-induced renal vasodilation mediated by nitric oxide. J Vasc Res 32:100–105

    PubMed  CAS  Google Scholar 

  32. McVicar AJ (1988) Dose-response effects of pressor doses of arginine vasopressin on renal haemodynamics in the rat. J Physiol (Lond) 404:535–546

    CAS  Google Scholar 

  33. Albanese J, Leone M, Delmas A, Martin C (2005) Terlipressin or norepinephrine in hyperdynamic septic shock: a prospective, randomized study. Crit Care Med 33:1897–1902

    Article  PubMed  CAS  Google Scholar 

  34. Boyle WA III, Segel LD (1986) Direct cardiac effects of vasopressin and their reversal by a vascular antagonist. Am J Physiol 251:H734–H741

    PubMed  CAS  Google Scholar 

  35. Walker BR, Childs ME, Adams EM (1988) Direct cardiac effects of vasopressin: role of V1- and V2-vasopressinergic receptors. Am J Physiol 255:H261–H265

    PubMed  CAS  Google Scholar 

  36. Imperiale TF, Teran JC, McCullough AJ (1995) A meta-analysis of somatostatin versus vasopressin in the management of acute esophageal variceal hemorrhage. Gastroenterology 109:1289–1294

    Article  PubMed  CAS  Google Scholar 

  37. Asfar P, Pierrot M, Veal N, Moal F, Oberti F, Croquet V, Douay O, Gallois Y, Saumet JL, Alquier P, Cales P (2003) Low-dose terlipressin improves systemic and splanchnic hemodynamics in fluid-challenged endotoxic rats. Crit Care Med 31:215–220

    Article  PubMed  CAS  Google Scholar 

  38. Thibonnier M, Conarty DM, Preston JA, Plesnicher CL, Dweik RA, Erzurum SC (1999) Human vascular endothelial cells express oxytocin receptors. Endocrinology 140:1301–1309

    Article  PubMed  CAS  Google Scholar 

  39. Okamura T, Toda M, Ayajiki K, Toda N (1997) Receptor subtypes involved in relaxation and contraction by arginine vasopressin in canine isolated short posterior ciliary arteries. J Vasc Res 34:464–472

    Article  PubMed  CAS  Google Scholar 

  40. Wallace AW, Tunin CM, Shoukas AA (1989) Effects of vasopressin on pulmonary and systemic vascular mechanics. Am J Physiol 257:H1228–H1234

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors thank Dr. Deborah Cook for reviewing the manuscript and Drs. Julie Abel, Dominique Bérard, Claude Cyr, Eric Deland, Sophie Laflamme, Marcel Martin, and Catherine St-Pierre for their help in recruiting patients.

Author information

Authors and Affiliations

  1. Soins Intensifs Médicaux et Chirurgicaux, Centre de Recherche Clinique, Centre Hospitalier Universitaire de Sherbrooke, 12ème Avenue Nord, 3001, J1H 5N4, Sherbrooke, QC, Canada

    François Lauzier & Olivier Lesur

  2. Service de Réanimation Médicale, Hôpital Central, Centre Hospitalier Universitaire de Nancy, Nancy, France

    Bruno Lévy

  3. Département de Pharmacie, Centre Hospitalier Universitaire de Sherbrooke, 12ème Avenue Nord, 3001, J1H 5N4, Sherbrooke, QC, Canada

    Patrice Lamarre

Authors
  1. François Lauzier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bruno Lévy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Patrice Lamarre
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Olivier Lesur
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Olivier Lesur.

Additional information

This work was supported by the Cardiovascular Critical Care research Network FRSQ and departmental funding.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lauzier, F., Lévy, B., Lamarre, P. et al. Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial. Intensive Care Med 32, 1782–1789 (2006). https://doi.org/10.1007/s00134-006-0378-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00134-006-0378-0

Keywords

Search

Navigation